Replies to post #105498 on Biotech Values

[mcbio]

Re: ACH-1625 Phase 2 trials

ACHN’s ACH-1625 study is actually two separate trials insofar as the doses to be used in the 12w+36w portion of the study will be determined after evaluating data from the 4w+44w portion of the study:

clinicaltrials.gov/ct2/show/NCT01180790

Yep, that's correct. Do you see anything out of the ordinary about the trials? I do like that ACHN is just testing QD doses as that leads me to believe that management is sufficiently confident that 1625 is a QD drug.